Would you offer PMRT to a pre-menopausal patient with early stage breast cancer, favorable biology, and an axillary dissection showing pN1a disease?

The role of PMRT in this situation remains controversial with factors considered including age/menopausal status, number of nodes, presence of ECE, receptor status, neoadjuvant chemo use, etc.

If the patient received neoadjuvant therapy and ypN1, I would offer PMRT.

If no neoadjuvant therapy, I often ...

I usually favor no RT unless adverse anatomical factors.